The data de-risk RP2 in uveal melanoma, a high-unmet-need indication with a 33.3% ORR and durable responses. Monitor enrollment updates and interim data from the ongoing Phase 2/3 trial (NCT06581406). The stock may re-rate on positive regulatory milestones, but no BLA or NDA is imminent.
REPL drugs
REPL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $9.00entry
- T+1 · 6mo ago −1.44%α −1.59% · $8.87
- T+5 · 5mo ago +5.22%α +7.97% · $9.47
- T+20 · 5mo ago +23.00%α +24.30% · $11.07
- T+60 · 3mo ago +75.56%α +74.32% · $15.80
Price Chart
How similar events traded
Executive Summary
Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in heavily pretreated advanced solid tumors, including a 33.3% ORR in uveal melanoma. The data support an ongoing randomized Phase 2/3 trial in uveal melanoma, but the filing is a clinical-stage update without regulatory approval or financial results, making it a notable but non-definitive catalyst.
Key Facts
- Phase 1 FIH study enrolled 85 heavily pretreated patients (median 2 prior lines; 42% prior ICI therapy).
- RP2 monotherapy ORR: 19.0% (4/21 evaluable); RP2 + nivolumab ORR: 19.1% (9/47 evaluable).
- Pooled ORR in uveal melanoma (where Phase 2/3 is enrolling): 33.3%.
- Median duration of response not reached in monotherapy (range 11.5–27.3+ months); 22.1 months in combination (range 2.8–35.2+ months).
- Tumor regression observed in both injected and non-injected lesions, indicating systemic immune response.
- No Grade 4 or 5 treatment-related adverse events; safety profile consistent with immune activation.
- Randomized Phase 2/3 trial in metastatic uveal melanoma (NCT06581406) is enrolling.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Phase 2/3 trial may fail to replicate Phase 1 efficacy in a larger, randomized setting.
- Competition from other oncolytic virus therapies and ICI combinations.
- No near-term revenue or regulatory filing catalyst; cash burn risk for clinical-stage biotech.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303918 |
Track record
32 reports on REPL
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers